Navigation Links
Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
Date:12/14/2009

is not successful in achieving a sale of assets, restructuring, financing or any combination thereof, the Company will have to curtail or cease operations, liquidate its assets or file for bankruptcy. The Company expects to make decisions in the near future.

For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion being unsuccessful in achieving its strategic alternatives, including any combination of a restructuring of the Company and its debt, a sale of the Company or its assets, and raising new capital, in which case it will curtail or cease operations, liquidate its assets or file for bankruptcy, the FDA requiring Vion to conduct a new randomized trial for Onrigin(TM) (laromustine) Injection prior to regulatory approval, Vion's potential inability to obtain regulatory approval for its products, particularly Onrigin(TM), delays in the regulatory approval process, particularly for Onrigin(TM), delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not confirmed by safety and efficacy results in later or final clinical trials, the need for additional research and testing, including the need for a randomized trial of Onrigin(TM) prior to regulatory approval, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, an
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  AbbVie (NYSE: ... several clinical studies evaluating potential new medicines in ... the upcoming 2014 European Society of Medical Oncology ... Madrid, Spain . Data being presented include ... safety and efficacy of veliparib (ABT-888), a poly ...
(Date:9/22/2014)... Sept. 22, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the ... 26, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. ... New York City . A ... under the investor relations section of Arena,s website at ...
(Date:9/22/2014)... -- According to the new market ... Media and Reagents), by Source, by type, by ... Testing, Research, Drug Discovery) - Analysis & Global ... studies the major market drivers, threats, opportunities, and ... tables and 64 figures spread through 225 pages ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... YORK, May 22, 2012  Fox Insurance Company, a Medicare ... announces the confirmation of a judgment in the arbitration ... manager, in excess of $3.3 million, following a suit ... breach of contract.  On May 21, 2012, the U.S. ...
Denmark...
Cached Medicine Technology:Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager 2
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 ... intensive care units (NICU) set up private rooms for parents ... Researchers at one children,s hospital found that preemies gained ... their NICU switched from the traditional "open-bay" layout to private ... in the journal Pediatrics , add to evidence that ...
(Date:9/22/2014)... Alan Mozes HealthDay Reporter ... Many American parents are aware of online physician-rating sites, and ... for their children, according to a new national study. ... parents -- further suggest that negative online ratings may dissuade ... been recommended by a neighbor. Conversely, a positive online ...
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
(Date:9/22/2014)... scientists have found that an anticonvulsant drug may help ... Although dozens of antibiotics target what bacteria do, their ... bacteria are created, and they found there is a ... important as there is growing concern worldwide about how ... The World Health Organization has declared that antibiotic resistance ...
(Date:9/22/2014)... PITTSBURGH, PA (PRWEB) September 22, 2014 ... caring for patients to the problem of side-sleeping. "My ... my side, so I designed a solution to this ... fall asleep comfortably than to have your arm 'fall ... sleep on his or her side more comfortably. It ...
Breaking Medicine News(10 mins):Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Looking ahead: Whole eye transplant under development 2
... Many baby boomers,incorrectly believe they have disability income ... Interactive(R) on behalf of America,s Health,Insurance Plans (AHIP). ... their income, but nearly half say they do ... http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), "Baby boomers recognize the ...
... JUPITER, Fla., May 22 Atlas Spine, Inc., ... fusion and non-fusion,products, announced today the national launch ... VBR is a radiolucent MIS compatible spacer,system designed ... of,various pathologies of the thoracic and lumbar spine., ...
... As Part Of Its Summer-Long Harley-Davidson ... 105th Anniversary Celebration Promotion, MILWAUKEE, May 22 ... Association (MDA) for every Miller Lite,bottle cap collected now through ... promotion. Miller Lite, the "ultimate light beer,",is the official beer ...
... 2008) The Foundation of the National Student Nurses ... New Jersey Regional Faculty Fellowships to two Rutgers College ... , The fellowship will help Ho-Shing, a Union, N.J. ... tuition, academic fees, and book expenses during the Fall ...
... Parental Reassurance, NEW YORK, May 22 ... biosensor and microprocessor technologies for,use in portable monitoring ... its latest homecare wellness product using SPO,s patented,technology ... home baby,monitor market., Each year, there are ...
... $4 MILLION INVESTMENT WILL SUPPORT AMERICA,S NEW GENERATION ... The National,Alliance for Hispanic Health (the Alliance) announced ... a new,partnership improving Hispanic student access to higher ... (STEM). The Program is,made possible through a $4 ...
Cached Medicine News:Health News:Many Baby Boomers Incorrectly Believe They Are Protected Against the Risk of Disability 2Health News:Many Baby Boomers Incorrectly Believe They Are Protected Against the Risk of Disability 3Health News:Atlas Spine Launches Stature(TM) Vertebral Body Replacement System 2Health News:Miller Lite Bottle Caps Equal Cash for MDA This Summer 2Health News:Miller Lite Bottle Caps Equal Cash for MDA This Summer 3Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 2Health News:SPO Medical Announces Entry into the Global Baby Monitor Consumer Market 3Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 2Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 3Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 4Health News:Elizabeth, NJ Chosen for Alliance/Merck Ciencia (Science) Hispanic Scholars Program 5
... Human Insulin-like growth factor binding protein-2 ... (further IGFBPs have been proposed) which specifically ... and IGF-II. The binding affinity of IGFBP-2 ... higher than for IGF-I [1], suggesting a ...
... Insulin-like growth factor binding protein-2 (IGFBP-2) is ... have been proposed) which specifically bind and ... The binding affinity of IGFBP-2 for IGF-II ... for IGF-I [1], suggesting a role in ...
... Androstenedione, produced in the adrenal gland and ... testosterone and estrone, both of which may ... relatively weak androgenic activity, estimated at ~(less ... [1]. However, serum androstenedione levels often exceed ...
... proteins that suppress the secretion of FSH ... consists of two distinct chains, or subunits ... consists of the alpha-subunit and betaA-subunit. Inhibin ... Only the dimeric forms of the molecule, ...
Medicine Products: